Scientific Production

UMR 1167

• Sims R et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat Genet. 2017 Sep;49(9):1373-1384.
• Dourlen P et al. Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology. Mol Psychiatry. 2017 Jun;22(6):874-883.
• Chapuis J, et al. Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism.Acta Neuropathol. 2017; 133 (6): 955-966).

UMR S 1172

• Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy ; Cyril Laurent et al ; BRAIN. 2017, 140, 184–200
• Tau deletion promotes brain insulin resistance ; Elodie Marciniak et al ; Exp. Med. 2017 Vol. 214 No. 8, 2257–2269,
• Plasma amyloid levels within the Alzheimer’s process and correlations with central biomarkers; Olivier Hannon et al. on behalf of the BALTAZAR study group; Alzheimer’s & Dementia.2018, 1-11 (6): 955-966).

UMR 1171

• Bergeron S, Chen Y, Auger F, Deguil J, Durieux N, Skrobala E, Barus R, Potey C, Cordonnier C, Pasquier F, Ravasi L, Bordet R, Gautier S, Role of cortical microbleeds in cognitive impairment: In vivo behavioral and imaging characterization of a novel murine model., Cereb. Blood Flow Metab., 2018 , 271678X17752765
• Patent « Radio-biopsie », MECA 17605 BETROUNI/AF-BR80078/BM/MAT/be. Demande de brevet déposée en Europe le 7 mars 2018 sous le n° EP18305244.8 aux noms de INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE LILLE et CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE LILLE
• Bournonville C, Hénon H, Dondaine T, Delmaire C, Bombois S, Mendyk AM, Cordonnier C, Moulin S, Leclerc X, Bordet R, Lopes R, Identification of a specific functional network altered in poststroke cognitive impairment., Neurology, 2018
• Delattre C, Bournonville C, Auger F, Lopes R, Delmaire C, Henon H, Mendyk AM, Bombois S, Devedjian JC, Leys D, Cordonnier C, Bordet R, Bastide M, Hippocampal Deformations and Entorhinal Cortex Atrophy as an Anatomical Signature of Long-Term Cognitive Impairment: from the MCAO Rat Model to the Stroke Patient., Transl Stroke Res, 2017
• Lopes R, Delmaire C, Defebvre L, Moonen AJ, Duits AA, Hofman P, Leentjens AF, Dujardin K1, Cognitive Phenotypes in Parkinson’s Disease Differ in Terms of Brain-Network Organization and Connectivity, Brain Mapp., 2017 , 1604-1621
• Hassan M, Chaton L, Benquet P, Delval A, Leroy C, Plomhause, Moonen AJ, Duits AA, Leentjens AF, van Kranen-Mastenbroek V, Defebvre L, Derambure P, Wendling F, Dujardin K, Functional connectivity disruptions correlate with cognitive phenotypes in Parkinson’s disease, NeuroImage-Clin., 2017 , 591-601
• Grolez G, Kyheng M, Lopes R, Moreau C, Timmerman K, Auger F, Kuchcinski G, Duhamel A, Jissendi-Tchofo P, Besson P, Laloux C, Petrault M, Devedjian JC, Pérez T, Pradat PF, Defebvre L, Bordet R, Danel-Brunaud V, Devos D, MRI of the cervical spinal cord predicts respiratory dysfunction in ALS, Sci Rep, 2018
• Baille G, Perez T, Devos D, Deken V, Defebvre L, Moreau C , Early occurrence of inspiratory muscle weakness in Parkinson”s disease, PLoS One, 2018
• Vanhoutte M, Semah F, Sillaire AR, Jaillard A, Petyt G, Kuchcinski G, Maureille A, Delbeuck X, Fahmi R, Pasquier F, Lopes R, F-18-FDG PET hypometabolism patterns reflect clinical heterogeneity in sporadic forms of early-onset Alzheimer’s disease, Aging, 2017 , 184-196
• Frequency of Cognitive Deficit and Associated Factors in a Cohort of Diabetic Patients; Marie Dumas, Julien Labreuche,Laetitia Coudert, Kathy Dujardin, Dominique Deplanque, Anne Vambergue, Stephanie Bombois. Alzheimer’s Association International Conference, juillet 2017; Londres Article en soumission
• Delval A, Defebvre L, Tard C , Freezing during tapping tasks in patients with advanced Parkinson’s disease and freezing of gait, PLoS One, 2017
• Lopes R, Delmaire C, Defebvre L, Moonen AJ, Duits AA, Hofman P, Leentjens AF, Dujardin K1, Cognitive Phenotypes in Parkinson’s Disease Differ in Terms of Brain-Network Organization and Connectivity, Brain Mapp., 2017 , 1604-1621
• Hassan M, Chaton L, Benquet P, Delval A, Leroy C, Plomhause, Moonen AJ, Duits AA, Leentjens AF, van Kranen-Mastenbroek V, Defebvre L, Derambure P, Wendling F, Dujardin K, Functional connectivity disruptions correlate with cognitive phenotypes in Parkinson’s disease, NeuroImage-Clin., 2017 , 591-601
• Leroy C, Bourriez JL, Dujardin K, Molaee-Ardekani B, Babiloni C, Deplanque D, Ponchel A, Hennion S, Plomhause L, Devanne H, Deguil J, Payoux P, Blin O, Méligne D, Micallef J, Chauveau N, Lanteaume L, Vervueren C, Guimont F, Thalamas C, Cassé-Perrot C, Rouby F, Bordet R, Derambure P; PharmaCog Consortium., A 15-day course of donepezil modulates spectral EEG dynamics related to target auditory stimuli in young, healthy adult volunteers., Clin Neurophysiol, 2015
• Laloux C, Gouel F, Lachaud C, Timmerman K, Do Van B, Jonneaux A, Petrault M, Garcon G, Rouaix N, Moreau C, Bordet R, Duce JA, Devedjian JC, Devos D, Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson’s disease?, Dis., 2017 , 24-31
• Two patents for  DIVE project – D DEVOS (Dopamine Intra VEntriculaire):
  • New therapeutic strategy of continuous dopaminergic stimulation in Parkinson’s disease for which the industrial transfer has been obtained. FR 1454254 (13th of May 2014),
  • New pharmaceutical composition comprising dopamine in anaerobic condition to treat Neurological and psychiatric disorders; and EP15305352.5 (9th of March 2015): Pharmaceutical solution comprising dopamine for use in treating Parkinson’s disease.
  • Three patents on GIFT project-D DEVOS (biotherapy: Growth factor preparations from platelets & neuroprotective strategies):
    • GIFTM0346 “Preparation of platelet pellet lysate and its use for treating neurological disorders “ EP16305332.5 (23/03/2016);
    • GIFT 2: M0346 process for preparing a pooled human platelet lysate, pooled human platelet lysate and its use fir treating neurological disorders –  EP17305739.9 (16/06/2017);
    • GIFT 3: M0493 Process for preparing a platelet lysate fraction, platelet lysate fraction and its use for treating disorders of the central nervous system – EP17306284.5 (27/09/2017)

• Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D, Iron as a therapeutic target for Parkinson’s disease., Disord., 2018
• Grolez G, Kyheng M, Lopes R, Moreau C, Timmerman K, Auger F, Kuchcinski G, Duhamel A, Jissendi-Tchofo P, Besson P, Laloux C, Petrault M, Devedjian JC, Pérez T, Pradat PF, Defebvre L, Bordet R, Danel-Brunaud V, Devos D, MRI of the cervical spinal cord predicts respiratory dysfunction in ALS, Sci Rep, 2018
• Moreau C, Danel V, Devedjian JC, Grolez G, Timmerman K, Laloux C, Petrault M, Gouel F, Jonneaux A, Dutheil M, Lachaud C, Lopes R, Kuchcinski G, Auger F, Kyheng M, Duhamel A, Pérez T, Pradat PF, Blasco H, Veyrat-Durebex C, Corcia P, Oeckl P, Otto M, Dupuis L, Garçon G, Defebvre L, Cabantchik ZI, Duce J, Bordet R, Devos D., Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis?, Redox Signal., 2017
• Duce JA, Wong BX, Durham H, Devedjian JC, Smith DP, Devos D , Post translational changes to alpha-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson’s disease, Neurodegener., 2017